Physician profile
Chanping Liang
NPI 1558386441
$14,704.58
in general payments reported to CMS, 2019-2025
20 companies · $3,623 in 2025
The $3,623 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,272 · 2020: $864 · 2021: $1,881 · 2022: $1,978 · 2023: $2,161 · 2024: $2,926 · 2025: $3,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,709.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,108.52 | 2022-2025 | |
| Sight Sciences, INC. | $2,667.96 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $2,622.55 | 2019-2025 | Hydrus Microstent, Clareon, Rocklatan |
| Allergan, INC. | $1,485.92 | 2019-2022 | |
| Glaukos Corporation | $1,170.24 | 2020-2024 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Idose |
| Bausch & Lomb Americas INC. | $841.60 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Dompe US, INC. | $320.23 | 2024-2025 | Oxervate |
| Horizon Therapeutics Plc | $318.60 | 2021-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $257.21 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $200.00 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2020 | |
| Alimera Sciences, INC. | $125.00 | 2022 | |
| Biotissue Holdings INC. | $104.89 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $100.00 | 2021 | |
| Topcon Healthcare, INC. | $85.93 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $82.09 | 2024-2025 | Tepezza |
| Ivantis, INC | $35.39 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $20.71 | 2025 | Acthar |
| New World Medical,INC. | $18.78 | 2023 | |
| Kala Pharmaceuticals, INC. | $13.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chanping Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.